Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:12603
Name acute leukemia
Definition A lymphoid leukemia that occurs when a hematopoietic stem cell undergoes malignant transformation into a primitive, undifferentiated cell with abnormal longevity producing large numbers of white blood cells to be produced and enter the blood stream.
Source DiseaseOntology.org
Alt Ids DOID:12621
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 wild-type SAR405838 acute leukemia sensitive detail...
KMT2A rearrange Pinometostat acute leukemia predicted - sensitive detail...
KMT2A rearrange Revumenib acute leukemia predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00602693 Phase I Sirolimus Allopurinol + Cyclophosphamide + Fludarabine T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Completed USA 0
NCT00990249 Phase II anti-thymocyte globulin + Busulfan + Clofarabine Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation Completed USA 0
NCT01028716 Phase II Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Terminated USA 0
NCT01822509 Phase I Ipilimumab + Nivolumab Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Completed USA 0
NCT02115295 Phase II Cladribine + Cytarabine + Idarubicin Midostaurin Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) Recruiting USA 0
NCT02135874 Phase II Clofarabine + Cytarabine + Dexamethasone + Idarubicin + Sorafenib + Vincristine Sulfate Clofarabine + Cytarabine + Dexamethasone + Idarubicin + Rituximab + Vincristine Sulfate Clofarabine + Cytarabine + Dexamethasone + Idarubicin + Vincristine Sulfate Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia Completed USA 0
NCT02141828 Phase I Pinometostat A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene Completed USA | CAN 0
NCT02208037 Phase II Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Completed USA 0
NCT02212561 Phase Ib/II Selinexor Cytarabine Cytarabine + Dexamethasone + Methotrexate Fludarabine Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT02225574 Phase Ib/II Binimetinib + Nilotinib An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T) Terminated USA 0
NCT02270788 Phase I Cytarabine + Leucovorin + Methotrexate Crenolanib + Sorafenib Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies Completed USA 0
NCT02345382 Phase I BAY1143572 Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia Completed USA | DEU 0
NCT02390752 Phase Ib/II Pexidartinib PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Recruiting USA 0
NCT02392572 Phase Ib/II ONC201 ONC201 in Relapsed/Refractory Acute Leukemias and High-risk Myelodysplastic Syndromes (HR-MDS) Recruiting USA 0
NCT02484261 Phase I Bortezomib + Pravastatin Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children Terminated USA 0
NCT02529813 Phase I Cyclophosphamide + Fludarabine + Tisagenlecleucel CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Completed USA 0
NCT02543879 Phase I FT-1101 Azacitidine + FT-1101 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Completed USA 0
NCT02551718 Phase I Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia Completed USA 0
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Active, not recruiting USA 0
NCT02727803 Phase II anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells Personalized NK Cell Therapy in CBT Recruiting USA 0
NCT02793544 Phase II Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Completed USA 0
NCT02828358 Phase II Cytarabine + Hydrocortisone + Leucovorin + Mercaptopurine + Pegaspargase Cyclophosphamide + Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Azacitidine Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Pegaspargase + Thioguanine + Vincristine sulfate liposome Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Mercaptopurine + Methotrexate Cyclophosphamide + Cytarabine + Thioguanine Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Active, not recruiting USA | CAN | AUS 1
NCT02879643 Phase I Dexamethasone + Methotrexate + Pegaspargase + Vincristine sulfate liposome Dexamethasone + Mercaptopurine + Methotrexate + Vincristine sulfate liposome Dexamethasone + Methotrexate + Mitoxantrone + Pegaspargase + Vincristine sulfate liposome Vincristine Sulfate Liposome Injection (Marqibo) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL Unknown status USA | CAN | AUS 0
NCT02879695 Phase I Blinatumomab + Ipilimumab + Nivolumab Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia Active, not recruiting USA 0
NCT03267186 Phase II Ibrutinib Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant Completed USA 0
NCT03386513 Phase Ib/II IMGN632 Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU 0
NCT03404193 Phase II Decitabine + Venetoclax Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-risk Myelodysplastic Syndrome Active, not recruiting USA 0
NCT03483324 Phase I AB-110 Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation Completed USA 0
NCT03519984 Phase I sEphB4-HSA + Vincristine sulfate liposome Cytarabine + sEphB4-HSA EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia Terminated USA 0
NCT03739606 Phase II Flotetuzumab Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Withdrawn 0
NCT03826992 Phase I CPX-351 + Venetoclax Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia Recruiting USA 0
NCT03834961 Phase II Larotrectinib Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia Active, not recruiting USA | CAN 0
NCT03959085 Phase III Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Leucovorin + Mercaptopurine + Methotrexate + Vincristine Sulfate Inotuzumab ozogamicin Cytarabine + Daunorubicin + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate Cytarabine + Daunorubicin + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Cyclophosphamide + Cytarabine + Methotrexate + Pegaspargase + Thioguanine + Vincristine Sulfate Inotuzumab ozogamicin + Methotrexate Methotrexate + Pegaspargase + Vincristine Sulfate Mercaptopurine + Methotrexate + Prednisolone + Vincristine Sulfate Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Recruiting USA | NZL | CAN | AUS 1
NCT04047641 Phase II Quizartinib Cladribine + Cytarabine + Idarubicin + Quizartinib Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting USA 0
NCT04681105 Phase I Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Active, not recruiting USA 0
NCT04811560 Phase I JNJ-75276617 A Study of JNJ-75276617 in Participants With Acute Leukemia Recruiting USA | GBR | FRA | ESP | AUS 0
NCT04898894 Phase I Cytarabine + Filgrastim + Fludarabine + Methotrexate + Selinexor + Venetoclax Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Recruiting USA 0
NCT04988555 Phase Ib/II DSP-5336 A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation Recruiting USA 1
NCT05005299 Phase I Cyclophosphamide + Fludarabine + Venetoclax Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (VICTORY) Recruiting AUS 0
NCT05153330 Phase I BMF-219 Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL With KMT2A/ MLL1r, NPM1 and Other Mutations Recruiting USA | NLD | ITA | ESP 1
NCT05521087 Phase I Cytarabine + Dexamethasone + Fludarabine + JNJ-75276617 + Pegaspargase + Vincristine Sulfate A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Not yet recruiting FRA 0
NCT05823571 Phase I Itacitinib Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Recruiting USA 0
NCT05918913 Expanded access Revumenib Expanded Access Program for SNDX-5613 Available USA 0
NCT06229912 Phase II Revumenib A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes Not yet recruiting USA 0